Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 19 of 19 for “"adalimumab"”.
-
Análisis costo versus efectividad del Etanercept, Infliximab y Adalimumab, en pacientes con artritis reumatoide refractaria
… (EPS) en Colombia: el Etanercept, Infliximab y Adalimumab. Dicho análisis se realizará de manera cuantitativa, para poder determinar cuál de ellos es la primera opción más costo-efectiva.
-
Eficacia y seguridad del biosimilar ABP 501 (Adalimumab) comparado con biosimilar CT-P13 (Infliximab) en pacientes adultos con artritis reumatoide. Revisión sistemática
… asociadas al tratamiento con Biosimilar ABP 501 (Adalimumab), Biosimilar CT-P13 (Infliximab). Metodología: Se realizó una revisión sistemática de la literatura que incluyó estudios de intervención, evaluando las respuestas clínicas de acuerdo a las escalas ACR20,ACR50, ACR 70 , DAS 28 PCR, y de …
-
Optimisation of analytical methods for monitoring monoclonal antibody therapy in Inflammatory Bowel Disease
… the monoclonal antibody therapies Infliximab and adalimumab. However, low drug levels and immunogenicity (development of anti-drug antibodies) are associated with treatment failure. Therapeutic drug monitoring, using drug and anti-drug antibody measurements improves treatment outcomes. This thesis …
-
Optimización del rango terapéutico de niveles de fármaco y anti-fármaco de terapia biológica anti-tnf-alfa en artritis reumatoide
… fármacos biológicos anti-TNF-alfa (infliximab, adalimumab y etanercept) ha mejorado el pronóstico, pero su eficacia puede verse afectada por la formación de anticuerpos antifármaco y estar condicionada por la variabilidad en niveles de fármaco. Este estudio se centra en la monitorización …
-
HIDRADENITIS SUPPURATIVA WITH 20 OR MORE DRAINING TUNNELS: A NATION-WIDE RETROSPECTIVE STUDY.
… patients with 20 or more dT were administered adalimumab, 12 received anti-IL17 agents, including secukinumab (9) and bimekizumab (3), and 9 were also offered off-label treatment options, including guselkumab (4), infliximab (3), risankizumab (1) and ustekinumab (1). At univariate regression …
-
Biologinės terapijos taikymas pacientams, sergantiems autoimuniniais artritais /
… incidence was detected in patients treated with adalimumab, lowest – in patients with infliximab. During treatment with BD short – term work disability decreased significantly, although the number of patients with long – term work disability did not chang. In our study we analyzed immunogenicity …
-
Biologic therapy in patients with autoimmune arthritis /
… incidence was detected in patients treated with adalimumab, lowest – in patients with infliximab. During treatment with BD short – term work disability decreased significantly, although the number of patients with long – term work disability did not chang. In our study we analyzed immunogenicity …
-
Clinical and epidemiologic aspects of Rheumatoid Arthritis. Special emphasis on cardiovascular outcome and risk factors
… to the background population. Treatment with adalimumab was associated with decreased expression of endothelial markers previously associated with severe systemic inflammation in RA. Smoking and a low level of formal education were independent risk factors for RA. Moderate alcohol consumption …
-
Estudio de las variaciones de los genes de la familia de la Interleucina 17 en pacientes con psoriasis
… que los pacientes psoriásicos tratados con adalimumab con el genotipo GG del SNP IL-17A rs7747909, alcanzaban porcentajes de respuesta mayores (81%) que los portadores del alelo A (AG+AA) (57%) (PASI75, semana 12; p=0,042). La ausencia de antecedentes familiares, y la presencia de …
-
Effect of Drugs on Rabbit Retina
… affected both retinal function and histology. Adalimumab, a monoclonal antibody against the pro-inflammatory cytokine tumor necrosis factor α is approved for subcutaneous injection in autoimmune diseases. The level of TNFα is raised in ocular inflammatory conditions. No functional disturbances …
-
Measure for measure. Outcome assessment of arthritis treatment in clinical practice
… with RA, PsA and SpA commencing treatment with adalimumab, etanercept or infliximab, date of treatment start and stop, core set variables and EQ-5D were recorded, and various activity indices, responses and EQ-5D utility were calculated. Descriptive statistics and completer analysis were used. …
-
Monoclonal Antibody Expression and Novel Purification in Nicotiana benthamiana
… (trastuzumab), Rituxan (rituximab), Humira (adalimumab) and Remicade (infliximab), which are cornerstones in this type of sector. With the cost of development to market approval rising astronomically for a new drug, new ways to produce and process these molecules becomes a paramount objective …
-
Approvals, Utilization, and Cost of Biologics for the Treatment of Rheumatoid Arthritis
… of biosimilars for infliximab, rituximab, and adalimumab. The annual cost at market entry was significantly positively correlated with FDA approval dates and TNFi classification.</p> <p><strong>Conclusions: </strong>The multifaceted nature of biologic therapy in RA management emphasizes the …
-
A Novel Interleukin-15 Receptor Antagonist for the Treatment of Rheumatoid Arthritis
… including methotrexate and biologics like adalimumab, have limited efficacy, leaving a substantial number of patients without adequate relief. Interleukin-15 (IL-15), a cytokine pivotal in RA pathogenesis, promotes inflammatory responses and is elevated in RA patients, highlighting it as a …
-
Therapeutic drug monitoring of anti-TNF biologics in patients with Crohn's disease at Groote Schuur Hospital, Cape Town, South Africa
… with an anti-TNF biologic, either infliximab or adalimumab, who underwent TDM since it was first implemented in the IBD clinic at Groote Schuur hospital, Cape Town, South Africa in between July 2018, and March 2023. Hospital records were analysed, and relevant demographic variables and clinical …
-
Genomic profiling of response to $\textit{in vivo}$ immune perturbations
… necrosis factor (TNF) drugs, infliximab and adalimumab. Anti-TNF treatment has revolutionised patient care for CD, but 20–40% of patients show primary non-response soon after starting treatment. I identified baseline expression modules associated with primary non-response, but also found …
-
Characterizing Inflammatory Mechanisms in Hidradenitis Suppurativa
… limited, with Tumor Necrosis Factor inhibitor adalimumab remaining the only approved biologic despite its limited efficacy. The development of novel therapeutics is impeded by our lack of understanding of disease pathogenesis and an absence of standardized approaches to study HS. In this …
-
Primary biliary cholangitis: genetic risk, phenotypic stratification and disease pathogenesis
… or anti-TNF-α monoclonal antibodies such as, adalimumab, used in the treatment of rheumatoid arthritis, Crohn’s disease and ulcerative colitis. Thirdly, that computational modelling can be used for phenotypic stratification in PBC to identify four novel subgroups each with distinct disease …